Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

OOS Therapies Inc

EconomyAI buildoutMarket MapFundsWatchlist
Log in
O

OS Therapies Inc

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
    Sep 24, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
    Sep 21, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
    Sep 17, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
    Sep 15, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
    Sep 8, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
    Sep 2, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
    Aug 17, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
    Aug 13, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
    Jul 8, 2026OS Therapies, Inc. (OSTX) Press Releases
  • OS Therapies Third Quarter 2026 Corporate Outlook
    Jul 6, 2026OS Therapies, Inc. (OSTX) Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions